{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:12:10Z","timestamp":1787026330710,"version":"build-2736575974"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atrial fibrillation (AF) is the most common sustained arrhythmia in adults and is associated with significant morbidity and mortality. Mitral stenosis (MS) is common in developing countries, affecting the younger population and posing a risk of atrial fibrillation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aims to delineate the clinical characteristics and poor outcomes in patients who have recent non-valvular AF (NVAF) compared with AF related to MS (MS-AF). Furthermore, it seeks to assess the healthcare resource utilization associated with the management of AF patients in the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>This is a prospective observational cohort conducted on 84 patients with recent AF. The patients were divided into two groups: the NVAF group (patients with no prosthetic valves or moderate\/severe MS) and the MS-AF group (patients with AF in the presence of moderate\/severe MS). The clinical characteristics, stroke risk, and anticoagulation regimens were assessed. AF-related outcomes (strokes, hospitalizations, major bleeding, and mortalities) were monitored and compared between the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean age of the studied AF patients was 49.80\u2009\u00b1\u200916.31 years, ranging from 25 to 89 years. Patients with MS-AF were significantly younger than patients with NVAF. Hypertension was the most prevalent risk factor associated with AF. Smoking, heart failure, and hypertension were more prevalent among patients with NVAF. The NVAF group received less anticoagulants than the MS-AF group. There were no statistically significant differences between the two groups regarding the overall incidence of death, stroke, myocardial infarction, TIA, or hospital admissions. In the overall studied group, all-cause mortality was higher among AF patients with a history of heart failure or stroke.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with NVAF had a significantly greater incidence of cardiovascular disease risk factors. However, AF related to mitral stenosis was associated with comparable worse outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2025.1555557","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T01:49:58Z","timestamp":1750211398000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical outcomes in recently diagnosed atrial fibrillation related to mitral stenosis compared to non-valvular atrial fibrillation"],"prefix":"10.3389","volume":"12","author":[{"given":"Mohamed","family":"Aboelhassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hosam","family":"Hasan-Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Taha","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Ashry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Aboel-Kassem F.","family":"Abdelmegid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.rec.2022.05.006","article-title":"2021 ESC\/EACTS guidelines for the management of valvular heart disease: developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"75","author":"Vahanian","year":"2022","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1093\/europace\/euq006","article-title":"Atrial fibrillation in Africa: clinical characteristics, prognosis, and adherence to guidelines in Cameroon","volume":"12","author":"Ntep-Gweth","year":"2010","journal-title":"Europace"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"American Heart Association Council on epidemiology and prevention statistics committee and stroke statistics subcommittee. Heart disease and stroke statistics-2019 update: a report from the American Heart Association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1160\/TH16-11-0825","article-title":"Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants","volume":"117","author":"Allan","year":"2017","journal-title":"Thromb Haemost"},{"key":"B6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/europace\/eur241","article-title":"Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options\u2013a report from the 3rd atrial fibrillation competence NETwork\/European Heart Rhythm Association consensus conference","volume":"14","author":"Kirchhof","year":"2012","journal-title":"Europace"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1161\/CIRCULATIONAHA.119.043391","article-title":"Global, regional, and national burden of calcific aortic valve and degenerative mitral valve diseases, 1990\u20132017","volume":"141","author":"Yadgir","year":"2020","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.acvd.2015.12.004","article-title":"The VALVAFRIC study: a registry of rheumatic heart disease in Western and Central Africa","volume":"109","author":"Kingu\u00e9","year":"2016","journal-title":"Arch Cardiovasc Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.cjca.2014.03.022","article-title":"Epidemiology of acquired valvular heart disease","volume":"30","author":"Iung","year":"2014","journal-title":"Can J Cardiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1136\/heartjnl-2017-311425","article-title":"Management of atrial fibrillation in patients with rheumatic mitral stenosis","volume":"104","author":"Iung","year":"2018","journal-title":"Heart"},{"key":"B11","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study","volume":"129","author":"Chugh","year":"2014","journal-title":"Circulation"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/eurheartj\/ehu449","article-title":"Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study)","volume":"36","author":"Z\u00fchlke","year":"2015","journal-title":"Eur Heart J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1093\/eurheartj\/ehv163","article-title":"Prognostic value of CHA2DS2-VASc score in patients with \u201cnon-valvular atrial fibrillation\u201d and valvular heart disease: the Loire Valley Atrial Fibrillation Project","volume":"36","author":"Philippart","year":"2015","journal-title":"Eur Heart J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e0185204","DOI":"10.1371\/journal.pone.0185204","article-title":"Clinical characteristics and 12-month outcomes of patients with valvular and non-valvular atrial fibrillation in Kenya","volume":"12","author":"Temu","year":"2017","journal-title":"PLoS One"},{"key":"B16","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.jacc.2006.10.062","article-title":"Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study","volume":"49","author":"Miyasaka","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.amjmed.2014.10.030","article-title":"Decade-long trends in atrial fibrillation incidence and survival: a community study","volume":"128","author":"Chamberlain","year":"2015","journal-title":"Am J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/eurheartj\/eht483","article-title":"Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke","volume":"35","author":"Piccini","year":"2014","journal-title":"Eur Heart J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1161\/CIRCOUTCOMES.110.959700","article-title":"Gulf survey of atrial fibrillation events (gulf SAFE): design and baseline characteristics of patients with atrial fibrillation in the Arab Middle East","volume":"4","author":"Zubaid","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1136\/hrt.2010.206938","article-title":"Predisposing factors and incidence of newly diagnosed atrial fibrillation in an urban African community: insights from the Heart of Soweto Study","volume":"96","author":"Sliwa","year":"2010","journal-title":"Heart"},{"key":"B21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5830\/CVJA-2012-064","article-title":"Clinical characteristics and outcomes of atrial fibrillation and flutter at the Aga Khan University Hospital, Nairobi","volume":"24","author":"Shavadia","year":"2013","journal-title":"Cardiovasc J Afr"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1093\/eurheartj\/ehm308","article-title":"Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm cohort-study of atrial fibrillation (SCAF)","volume":"28","author":"Friberg","year":"2007","journal-title":"Eur Heart J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1161\/01.CIR.0000118472.77237.FA","article-title":"Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study","volume":"109","author":"Steinberg","year":"2004","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1161\/CIRCULATIONAHA.112.000491","article-title":"Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study","volume":"128","author":"Marijon","year":"2013","journal-title":"Circulation"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e002197","DOI":"10.1161\/JAHA.115.002197","article-title":"Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF","volume":"5","author":"Pokorney","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"B26","doi-asserted-by":"publisher","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1161\/CIRCOUTCOMES.108.796185","article-title":"Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review","volume":"1","author":"Wan","year":"2008","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"B29","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1161\/CIRCOUTCOMES.112.967299","article-title":"National trends in oral anticoagulant use in the United States, 2007 to 2011","volume":"5","author":"Kirley","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"B30","first-page":"2422","article-title":"Atrial fibrillation management: a prospective survey in ESC member countries: the Euro heart survey on atrial fibrillation","volume-title":"Eur Heart J","author":"Nieuwlaat","year":"2005"},{"key":"B31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ijcard.2004.12.042","article-title":"Retrospective investigation of hospitalised patients with atrial fibrillation in mainland China","volume":"105","author":"Wen-Hang","year":"2005","journal-title":"Int J Cardiol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/jamacardio.2016.1025","article-title":"Racial differences in atrial fibrillation-related cardiovascular disease and mortality: the Atherosclerosis Risk in Communities (ARIC) study","volume":"1","author":"Magnani","year":"2016","journal-title":"JAMA Cardiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1136\/hrt.2002.008748","article-title":"Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK","volume":"90","author":"Stewart","year":"2004","journal-title":"Heart"},{"key":"B34","doi-asserted-by":"publisher","first-page":"ii9","DOI":"10.1093\/europace\/eur087","article-title":"What are the costs of atrial fibrillation?","volume":"13","author":"Blomstrom Lundqvist","year":"2011","journal-title":"Europace"},{"key":"B35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1524-4733.2006.00160.x","article-title":"The impact of atrial fibrillation on the cost of stroke: the Berlin acute stroke study","volume":"10","author":"Br\u00fcggenj\u00fcrgen","year":"2007","journal-title":"Value Health"},{"key":"B36","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/archinternmed.2012.878","article-title":"The increasing burden of atrial fibrillation compared with heart failure and myocardial infarction: a 15-year study of all hospitalizations in Australia","volume":"172","author":"Wong","year":"2012","journal-title":"Arch Intern Med"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1555557\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T01:49:59Z","timestamp":1750211399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1555557\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":36,"alternative-id":["10.3389\/fcvm.2025.1555557"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1555557","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"article-number":"1555557"}}